2,477 results on '"Kjaer, Susanne K."'
Search Results
2. Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium
- Author
-
Nagle, Christina M., Ibiebele, Torukiri I., Bandera, Elisa V., Cramer, Daniel, Doherty, Jennifer A., Giles, Graham G., Goodman, Marc T., Hanley, Gillian E., Harris, Holly R., Jensen, Allan, Kjaer, Susanne K., Lee, Alice W., Milne, Roger L., Qin, Bo, Richardson, Jean, Sasamoto, Naoko, Sieh, Weiva, Terry, Kathryn L., Titus, Linda, Trabert, Britton, Wentzensen, Nicolas, Wu, Anna H., Berchuck, Andrew, Pike, Malcolm, Pearce, Celeste Leigh, and Webb, Penelope M. more...
- Published
- 2024
- Full Text
- View/download PDF
Catalog
3. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease
- Author
-
Ramachandran, Dhanya, Tyrer, Jonathan P, Kommoss, Stefan, DeFazio, Anna, Riggan, Marjorie J, Webb, Penelope M, Fasching, Peter A, Lambrechts, Diether, García, María J, Rodríguez-Antona, Cristina, Goodman, Marc T, Modugno, Francesmary, Moysich, Kirsten B, Karlan, Beth Y, Lester, Jenny, Kjaer, Susanne K, Jensen, Allan, Høgdall, Estrid, Goode, Ellen L, Cliby, William A, Kumar, Amanika, Wang, Chen, Cunningham, Julie M, Winham, Stacey J, Monteiro, Alvaro N, Schildkraut, Joellen M, Cramer, Daniel W, Terry, Kathryn L, Titus, Linda, Bjorge, Line, Thomsen, Liv Cecilie Vestrheim, Pejovic, Tanja, Høgdall, Claus K, McNeish, Iain A, May, Taymaa, Huntsman, David G, Pfisterer, Jacobus, Canzler, Ulrich, Park-Simon, Tjoung-Won, Schröder, Willibald, Belau, Antje, Hanker, Lars, Harter, Philipp, Sehouli, Jalid, Kimmig, Rainer, de Gregorio, Nikolaus, Schmalfeldt, Barbara, Baumann, Klaus, Hilpert, Felix, Burges, Alexander, Winterhoff, Boris, Schürmann, Peter, Speith, Lisa-Marie, Hillemanns, Peter, Berchuck, Andrew, Johnatty, Sharon E, Ramus, Susan J, Chenevix-Trench, Georgia, Pharoah, Paul DP, Dörk, Thilo, and Heitz, Florian more...
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Genetics ,Cancer ,Prevention ,Human Genome ,Clinical Research ,Ovarian Cancer ,Women's Health ,Orphan Drug ,Rare Diseases ,2.1 Biological and endogenous factors ,AOCS Group ,OPAL Study Group ,Medical biotechnology - Abstract
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous carcinoma (HGSOC), to identify variants associated with residual disease. The most significant association with resection status was observed for rs72845444, upstream of MGMT, in HGSOC (p = 3.9 × 10-8). In gene-based analyses, PPP2R5C was the most strongly associated gene in HGSOC after stage adjustment. In an independent set of 378 ovarian tumours from the AGO-OVAR 11 study, variants near MGMT and PPP2R5C correlated with methylation and transcript levels, and PPP2R5C mRNA levels predicted progression-free survival in patients with residual disease. MGMT encodes a DNA repair enzyme, and PPP2R5C encodes the B56γ subunit of the PP2A tumour suppressor. Our results link heritable variation at these two loci with resection status in HGSOC. more...
- Published
- 2024
4. Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden
- Author
-
Zheng, Guoqiao, Faber, Mette Tuxen, Wang, Jiangrong, Baandrup, Louise, Hertzum-Larsen, Rasmus, Sundström, Karin, and Kjær, Susanne K.
- Published
- 2024
- Full Text
- View/download PDF
5. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis
- Author
-
May, Taymaa, Bernardini, Marcus, Lheureux, Stephanie, Aben, Katja KH, Bandera, Elisa V, Beckmann, Matthias W, Benitez, Javier, Berchuck, Andrew, Bjørge, Line, Carney, Michael E, Cramer, Daniel W, deFazio, Anna, Dörk, Thilo, Eccles, Diana M, Friedlander, Michael, García, María Jose, Goode, Ellen L, Hein, Alexander, Høgdall, Claus K, Jensen, Allan, Johnatty, Sharon, Kennedy, Catherine J, Kiemeney, Lambertus A, Kjær, Susanne K, Kupryjańczyk, Jolanta, Matsuo, Keitaro, McGuire, Valerie, Modugno, Francesmary, Paddock, Lisa E, Pejovic, Tanja, Phelan, Catherine M, Riggan, Marjorie J, Rodriguez-Antona, Cristina, Rothstein, Joseph H, Sieh, Weiva, Song, Honglin, Terry, Kathryn L, van Altena, Anne M, Vanderstichele, Adriaan, Vergote, Ignace, Thomsen, Liv Cecilie Vestrheim, Webb, Penelope M, Wentzensen, Nicolas, Wilkens, Lynne R, Ziogas, Argyrios, Jiang, Haiyan, and Tone, Alicia more...
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Ovarian Cancer ,Cancer ,Clinical Research ,Rare Diseases ,6.4 Surgery ,Evaluation of treatments and therapeutic interventions ,Humans ,Female ,Middle Aged ,Retrospective Studies ,Neoplasm Staging ,Ovarian Neoplasms ,Cystadenocarcinoma ,Serous ,Kaplan-Meier Estimate ,Ovarian Cancer Association and the Australian Ovarian Cancer Study Group ,Clinical Sciences ,Surgery ,Clinical sciences - Abstract
BackgroundWomen with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.MethodsWe performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.ResultsOf the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.ConclusionThis multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice. more...
- Published
- 2023
6. Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study
- Author
-
Lindquist, Sofie, Kjær, Susanne K., Frederiksen, Kirsten, Ørnskov, Dorthe, Munk, Christian, and Waldstrøm, Marianne
- Published
- 2024
- Full Text
- View/download PDF
7. Human papillomavirus-associated cancers, precancers, and genital warts in Denmark, 2000–2022 – Current burden of disease and population impact of multi-cohort HPV vaccination
- Author
-
Kaderly Rasmussen, Emma L., Lindquist, Sofie, Baandrup, Louise, Hansen, Tatiana, Munk, Christian, Frederiksen, Kirsten, and Kjær, Susanne K.
- Published
- 2024
- Full Text
- View/download PDF
8. Effects of risk factors for ovarian cancer in women with and without endometriosis
- Author
-
Phung, Minh Tung, Muthukumar, Aruna, Trabert, Britton, Webb, Penelope M, Jordan, Susan J, Terry, Kathryn L, Cramer, Daniel W, Titus, Linda J, Risch, Harvey A, Doherty, Jennifer Anne, Harris, Holly R, Goodman, Marc T, Modugno, Francesmary, Moysich, Kirsten B, Jensen, Allan, Kjaer, Susanne K, Anton-Culver, Hoda, Ziogas, Argyrios, Berchuck, Andrew, Khoja, Lilah, Wu, Anna H, Pike, Malcolm C, Pearce, Celeste Leigh, and Lee, Alice W more...
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Contraception/Reproduction ,Cancer ,Prevention ,Endometriosis ,Aging ,Estrogen ,Clinical Research ,Ovarian Cancer ,Clinical Trials and Supportive Activities ,2.1 Biological and endogenous factors ,Aetiology ,Female ,Humans ,Talc ,Ovarian Neoplasms ,Carcinoma ,Ovarian Epithelial ,Risk Factors ,Case-Control Studies ,Estrogens ,ovarian cancer ,effect modification ,risk factors ,interactions ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Public Health and Health Services ,Obstetrics & Reproductive Medicine ,Reproductive medicine - Abstract
ObjectiveTo evaluate the associations between 10 well-established ovarian cancer risk factors and risk of ovarian cancer among women with vs. without endometriosis.DesignPooled analysis of 9 case-control studies in the Ovarian Cancer Association Consortium.SettingPopulation-based.Patient(s)We included 8,500 women with ovarian cancer, 13,592 control women.Intervention(s)Ten well-established ovarian cancer risk factors.Main outcome measure(s)Risk of ovarian cancer for women with and without endometriosis.Result(s)Most risk factor-ovarian cancer associations were similar when comparing women with and without endometriosis, and no interactions were statistically significant. However, body mass index (BMI) 25- more...
- Published
- 2022
9. A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer
- Author
-
Faber, Mette T, Frederiksen, Kirsten, Palefsky, Joel M, and Kjaer, Susanne K
- Subjects
HIV/AIDS ,Prevention ,Cancer ,Clinical Research ,Infectious Diseases ,2.1 Biological and endogenous factors ,Aetiology ,Good Health and Well Being ,Anus Neoplasms ,Carcinoma in Situ ,Carcinoma ,Squamous Cell ,Cohort Studies ,HIV Infections ,Homosexuality ,Male ,Humans ,Longitudinal Studies ,Male ,Papillomavirus Infections ,Risk Factors ,anal cancer ,anal intraepithelial neoplasia ,progression ,risk factors ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Little is known about risk factors for progression of high-grade anal intraepithelial neoplasia (AIN) to anal squamous cell carcinoma (ASCC). In this large, population-based study, we assess the role of factors related to immune status for the risk of ASCC among individuals from the general population with a diagnosis of AIN3. Individuals diagnosed with AIN3 during 1985-2016 were identified in the Danish Pathology Registry and followed for subsequent development of ASCC. The study population was linked to the National Patient Registry, the Danish Prescription Registry and the Danish HIV Cohort Study for information on autoimmune disease, genital warts and HIV status. To study the progression rate, Cox regression models with hazard ratios (HR) and 95% confidence intervals (CI) were applied with time since AIN3 as the underlying time scale and with adjustment for age at AIN3 diagnosis, year of AIN3 diagnosis and sex. The study population comprised 1222 individuals with AIN3 contributing 12 824 person-years of follow-up. Ninety-seven individuals (7.9%) developed ASCC. Individuals registered with an autoimmune disease or genital warts before and/or after the AIN3 diagnosis had an increased rate of progression to ASCC compared to individuals without these conditions. People living with HIV had a higher progression rate than HIV-negative individuals (HR = 4.25; 95% CI: 1.87-9.65) with the highest progression rate among those with CD4 count ≤200 cells/μL. These associations may be caused by an interplay between HPV infection and immunosuppression. more...
- Published
- 2022
10. Incidence and clearance of cervical and anal high-risk human papillomavirus in kidney transplant recipients: Results from a Danish prospective clinical study
- Author
-
Ring, Linea Landgrebe, Larsen, Helle Kiellberg, Frederiksen, Kirsten, Hædersdal, Merete, Sørensen, Søren Schwartz, Bonde, Jesper Hansen, Thomsen, Louise Thirstrup, and Kjær, Susanne K.
- Published
- 2024
- Full Text
- View/download PDF
11. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
- Author
-
Dareng, Eileen O., Coetzee, Simon G., Tyrer, Jonathan P., Peng, Pei-Chen, Rosenow, Will, Chen, Stephanie, Davis, Brian D., Dezem, Felipe Segato, Seo, Ji-Heui, Nameki, Robbin, Reyes, Alberto L., Aben, Katja K.H., Anton-Culver, Hoda, Antonenkova, Natalia N., Aravantinos, Gerasimos, Bandera, Elisa V., Beane Freeman, Laura E., Beckmann, Matthias W., Beeghly-Fadiel, Alicia, Benitez, Javier, Bernardini, Marcus Q., Bjorge, Line, Black, Amanda, Bogdanova, Natalia V., Bolton, Kelly L., Brenton, James D., Budzilowska, Agnieszka, Butzow, Ralf, Cai, Hui, Campbell, Ian, Cannioto, Rikki, Chang-Claude, Jenny, Chanock, Stephen J., Chen, Kexin, Chenevix-Trench, Georgia, Chiew, Yoke-Eng, Cook, Linda S., DeFazio, Anna, Dennis, Joe, Doherty, Jennifer A., Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana M., Ene, Gabrielle, Fasching, Peter A., Flanagan, James M., Fortner, Renée T., Fostira, Florentia, Gentry-Maharaj, Aleksandra, Giles, Graham G., Goodman, Marc T., Gronwald, Jacek, Haiman, Christopher A., Håkansson, Niclas, Heitz, Florian, Hildebrandt, Michelle A.T., Høgdall, Estrid, Høgdall, Claus K., Huang, Ruea-Yea, Jensen, Allan, Jones, Michael E., Kang, Daehee, Karlan, Beth Y., Karnezis, Anthony N., Kelemen, Linda E., Kennedy, Catherine J., Khusnutdinova, Elza K., Kiemeney, Lambertus A., Kjaer, Susanne K., Kupryjanczyk, Jolanta, Labrie, Marilyne, Lambrechts, Diether, Larson, Melissa C., Le, Nhu D., Lester, Jenny, Li, Lian, Lubiński, Jan, Lush, Michael, Marks, Jeffrey R., Matsuo, Keitaro, May, Taymaa, McLaughlin, John R., McNeish, Iain A., Menon, Usha, Missmer, Stacey, Modugno, Francesmary, Moffitt, Melissa, Monteiro, Alvaro N., Moysich, Kirsten B., Narod, Steven A., Nguyen-Dumont, Tu, Odunsi, Kunle, Olsson, Håkan, Onland-Moret, N. Charlotte, Park, Sue K., Pejovic, Tanja, Permuth, Jennifer B., Piskorz, Anna, Prokofyeva, Darya, Riggan, Marjorie J., Risch, Harvey A., Rodríguez-Antona, Cristina, Rossing, Mary Anne, Sandler, Dale P., Setiawan, V. Wendy, Shan, Kang, Song, Honglin, Southey, Melissa C., Steed, Helen, Sutphen, Rebecca, Swerdlow, Anthony J., Teo, Soo Hwang, Terry, Kathryn L., Thompson, Pamela J., Vestrheim Thomsen, Liv Cecilie, Titus, Linda, Trabert, Britton, Travis, Ruth, Tworoger, Shelley S., Valen, Ellen, Van Nieuwenhuysen, Els, Edwards, Digna Velez, Vierkant, Robert A., Webb, Penelope M., Weinberg, Clarice R., Weise, Rayna Matsuno, Wentzensen, Nicolas, White, Emily, Winham, Stacey J., Wolk, Alicja, Woo, Yin-Ling, Wu, Anna H., Yan, Li, Yannoukakos, Drakoulis, Zeinomar, Nur, Zheng, Wei, Ziogas, Argyrios, Berchuck, Andrew, Goode, Ellen L., Huntsman, David G., Pearce, Celeste L., Ramus, Susan J., Sellers, Thomas A., Freedman, Matthew L., Lawrenson, Kate, Schildkraut, Joellen M., Hazelett, Dennis, Plummer, Jasmine T., Kar, Siddhartha, Jones, Michelle R., Pharoah, Paul D.P., and Gayther, Simon A. more...
- Published
- 2024
- Full Text
- View/download PDF
12. Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women
- Author
-
Kristensen, Anna Kjær, Frandsen, Clarissa Lima Brown, Nøhr, Bugge, Viuff, Jakob Hansen, Hargreave, Marie, Frederiksen, Kirsten, Kjær, Susanne K., and Jensen, Allan
- Published
- 2024
- Full Text
- View/download PDF
13. Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study
- Author
-
Yahyavi, Sam Kafai, Holt, Rune, Knudsen, Nadia Krarup, Andreassen, Christine Hjorth, Sejling, Christoffer, Meddis, Alessandra, Kjaer, Susanne K., Schwarz, Peter, Jensen, Jens-Erik Beck, Torp-Pedersen, Christian, Juul, Anders, Selmer, Christian, and Blomberg Jensen, Martin more...
- Published
- 2024
- Full Text
- View/download PDF
14. Prevalence of cervical human papillomavirus in kidney transplant recipients: A systematic review and meta-analysis
- Author
-
Ring, Linea Landgrebe, Lindquist, Sofie, Rosthøj, Susanne, Larsen, Helle K., Hædersdal, Merete, Sørensen, Søren S., Kjaer, Susanne K., and Sand, Freja Lærke
- Published
- 2024
- Full Text
- View/download PDF
15. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis
- Author
-
Wohlmuth, Christoph, Djedovic, Vladimir, Kjaer, Susanne K, Jensen, Allan, Glasspool, Rosalind, Roxburgh, Patricia, DeFazio, Anna, Johnatty, Sharon E, Webb, Penelope M, Modugno, Francesmary, Lambrechts, Diether, Schildkraut, Joellen M, Berchuck, Andrew, Thomsen, Liv Cecilie Vestrheim, Bjorge, Line, Høgdall, Estrid, Høgdall, Claus K, Goode, Ellen L, Winham, Stacey J, Matsuo, Keitaro, Karlan, Beth Y, Lester, Jenny, Goodman, Marc T, Thompson, Pamela J, Pejovic, Tanja, Riggan, Marjorie J, Lajkosz, Katherine, Tone, Alicia, and May, Taymaa more...
- Subjects
Cancer ,Prevention ,Clinical Research ,Rare Diseases ,Ovarian Cancer ,ovarian cancer ,low-grade serous cancer ,CA-125 ,survival ,Oncology and Carcinogenesis - Abstract
ObjectiveStudies on low-grade serous ovarian cancer (LGSC) are limited by a low number of cases. The aim of this study was to define the prognostic significance of age, stage, and CA-125 levels on survival in a multi-institutional cohort of women with pathologically confirmed LGSC.MethodsWomen with LGSC were identified from the collaborative Ovarian Cancer Association Consortium (OCAC). Cases of newly diagnosed primary LGSC were included if peri-operative CA-125 levels were available. Age at diagnosis, FIGO stage, pre- and post-treatment CA-125 levels, residual disease, adjuvant chemotherapy, disease recurrence, and vital status were collected by the participating institutions. Progression-free (PFS) and overall survival (OS) were calculated. Multivariable (MVA) Cox proportional hazard models were used and hazard ratios (HR) calculated.ResultsA total of 176 women with LGSC were included in this study; 82% had stage III/IV disease. The median PFS was 2.3 years and the median OS was 6.4 years. Age at diagnosis was not significantly associated with worse PFS (p = 0.23) or OS (p = 0.3) (HR per year: 0.99; 95%CI, 0.96-1.01 and 0.98; 95%CI 0.95-1.01). FIGO stage III/IV was independently associated with PFS (HR 4.26, 95%CI 1.43-12.73) and OS (HR 1.69, 95%CI 0.56-5.05). Elevated CA-125 (≥35 U/mL) at diagnosis was not significantly associated with worse PFS (p = 0.87) or OS (p = 0.78) in MVA. Elevated CA-125 (≥35 U/mL) after completion of primary treatment was independently associated with worse PFS (HR 2.81, 95%CI 1.36-5.81) and OS (HR 6.62, 95%CI 2.45-17.92). In the MVA, residual disease was independently associated with PFS (0.022), but not OS (0.85).ConclusionAdvanced LGSC was associated with poor long-term prognosis. FIGO stage and abnormal post-treatment CA-125 level are key prognostic factors inversely associated with PFS and OS.Highlights1. Through a multi-center collaborative effort, data from 176 women with low-grade serous ovarian cancer were analyzed. 2. Although low-grade serous ovarian cancer is often considered indolent, the progression-free and overall survival are poor. 3. Elevated post-treatment CA-125 levels are independently associated with poor survival. more...
- Published
- 2022
16. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
- Author
-
Khoja, Lilah, Weber, Rachel Palmieri, Group, The Australian Ovarian Cancer Study, Webb, Penelope M, Jordan, Susan J, Muthukumar, Aruna, Chang-Claude, Jenny, Fortner, Renée T, Jensen, Allan, Kjaer, Susanne K, Risch, Harvey, Doherty, Jennifer Anne, Harris, Holly R, Goodman, Marc T, Modugno, Francesmary, Moysich, Kirsten, Berchuck, Andrew, Schildkraut, Joellen M, Cramer, Daniel, Terry, Kathryn L, Anton-Culver, Hoda, Ziogas, Argyrios, Phung, Minh Tung, Hanley, Gillian E, Wu, Anna H, Mukherjee, Bhramar, McLean, Karen, Cho, Kathleen, Pike, Malcolm C, Pearce, Celeste Leigh, and Lee, Alice W more...
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Endometriosis ,Ovarian Cancer ,Rare Diseases ,Contraception/Reproduction ,Clinical Research ,Estrogen ,2.1 Biological and endogenous factors ,Aetiology ,Case-Control Studies ,Estrogen Replacement Therapy ,Female ,Humans ,Hysterectomy ,Menopause ,Ovarian Neoplasms ,Ovarian cancer ,Hormone therapy ,Australian Ovarian Cancer Study Group ,Paediatrics and Reproductive Medicine ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis ,Reproductive medicine - Abstract
ObjectiveTo evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.MethodsWe conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95% confidence intervals (CIs).ResultsOverall and among women without endometriosis, there was a positive association between ovarian cancer risk and hysterectomy (OR = 1.19, 95% CI 1.09-1.31 and OR = 1.20, 95% CI 1.09-1.32, respectively), but no association upon adjusting for duration of ET and EPT use (OR = 1.04, 95% CI 0.94-1.16 and OR = 1.06, 95% CI 0.95-1.18, respectively). Among women with a history of endometriosis, there was a slight inverse association between hysterectomy and ovarian cancer risk (OR = 0.93, 95% CI 0.69-1.26), but this association became stronger and statistically significant after adjusting for duration of ET and EPT use (OR = 0.69, 95% CI 0.48-0.99).ConclusionsThe hysterectomy-ovarian cancer association is complex and cannot be understood without considering duration of ET and EPT use and history of endometriosis. Failure to take these exposures into account in prior studies casts doubt on their conclusions. Overall, hysterectomy is not risk-reducing for ovarian cancer, however the inverse association among women with endometriosis warrants further investigation. more...
- Published
- 2022
17. History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study
- Author
-
Hannibal, Charlotte Gerd, Kjaer, Susanne K., Galanakis, Michael, Hertzum-Larsen, Rasmus, Maltesen, Thomas, and Baandrup, Louise
- Published
- 2024
- Full Text
- View/download PDF
18. Maternal use of hormonal contraception and risk of childhood autism spectrum disorders: A Parental Exposures and Child Health (PECH) cohort study
- Author
-
Hargreave, Marie, Jezek, Andrea H, Hemmingsen, Caroline H, Andersen, Elisabeth AW, Pagsberg, Anne K, Holmberg, Teresa, Mørch, Lina S, and Kjaer, Susanne K
- Published
- 2024
- Full Text
- View/download PDF
19. Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study
- Author
-
Urbute, Aivara, Frederiksen, Kirsten, Thomsen, Louise T., Kesmodel, Ulrik Schiøler, and Kjaer, Susanne K.
- Published
- 2024
- Full Text
- View/download PDF
20. Educational differences in healthcare use among survivors after breast, prostate, lung, and colon cancer – a SEQUEL cohort study
- Author
-
Levinsen, Anne Katrine Graudal, Kjaer, Trille Kristina, Maltesen, Thomas, Jakobsen, Erik, Gögenur, Ismail, Borre, Michael, Christiansen, Peer, Zachariae, Robert, Laurberg, Søren, Christensen, Peter, Kroman, Niels, Larsen, Signe Benzon, Degett, Thea Helene, Hölmich, Lisbet Rosenkrantz, Brown, Peter de Nully, Johansen, Christoffer, Kjær, Susanne K., Thygesen, Lau Caspar, and Dalton, Susanne Oksbjerg more...
- Published
- 2023
- Full Text
- View/download PDF
21. Knowledge on human papilloma virus and experience of getting positive results: a qualitative study among women in Kilimanjaro, Tanzania
- Author
-
Swai, Patricia, Mgongo, Melina, Leyaro, Beatrice J., Mwaiselage, Julius, Mchome, Bariki L., Kjaer, Susanne K., Rasch, Vibeke, Manongi, Rachel, and Msuya, Sia E.
- Published
- 2023
- Full Text
- View/download PDF
22. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
- Author
-
Quinn, Michael CJ, McCue, Karen, Shi, Wei, Johnatty, Sharon E, Beesley, Jonathan, Civitarese, Andrew, O'Mara, Tracy A, Glubb, Dylan M, Tyrer, Jonathan P, Armasu, Sebastian M, Ong, Jue-Sheng, Gharahkhani, Puya, Lu, Yi, Gao, Bo, Patch, Ann-Marie, Fasching, Peter A, Beckmann, Matthias W, Lambrechts, Diether, Vergote, Ignace, Edwards, Digna R Velez, Beeghly-Fadiel, Alicia, Benitez, Javier, Garcia, Maria J, Goodman, Marc T, Dörk, Thilo, Dürst, Matthias, Modugno, Francesmary, Moysich, Kirsten, du Bois, Andreas, Pfisterer, Jacobus, Bauman, Klaus, Group, for the AGO Study, Karlan, Beth Y, Lester, Jenny, Cunningham, Julie M, Larson, Melissa C, McCauley, Bryan M, Kjaer, Susanne K, Jensen, Allan, Hogdall, Claus K, Hogdall, Estrid, Schildkraut, Joellen M, Riggan, Marjorie J, Berchuck, Andrew, Cramer, Daniel W, Terry, Kathryn L, Bjorge, Line, Webb, Penelope M, Group, for the OPAL Study, Friedlander, Michael, Pejovic, Tanja, Moffitt, Melissa, Glasspool, Rosalind, May, Taymaa, Ene, Gabrielle EV, Huntsman, David G, Woo, Michelle, Carney, Michael E, Hinsley, Samantha, Heitz, Florian, Fereday, Sian, Kennedy, Catherine J, Edwards, Stacey L, Winham, Stacey J, deFazio, Anna, Group, for Australian Ovarian Cancer Study, Pharoah, Paul DP, Goode, Ellen L, MacGregor, Stuart, and Chenevix-Trench, Georgia more...
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Human Genome ,Cancer ,Genetics ,Ovarian Cancer ,Rare Diseases ,Aetiology ,2.1 Biological and endogenous factors ,Autophagy-Related Protein-1 Homolog ,Biomarkers ,Tumor ,Carcinoma ,Ovarian Epithelial ,Female ,Gene Knockout Techniques ,Genome-Wide Association Study ,Humans ,Intracellular Signaling Peptides and Proteins ,Ovarian Neoplasms ,Polymorphism ,Single Nucleotide ,Progression-Free Survival ,AGO Study Group ,OPAL Study Group ,for Australian Ovarian Cancer Study Group ,Medical and Health Sciences ,Epidemiology ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundMany loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance.MethodsWe carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy.ResultsWe found seven SNPs at 12q24.33 associated with PFS (P < 5 × 10-8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15-1.34; P = 1.47 × 10-8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro.ConclusionsThe locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association.ImpactThis finding provides insight into genetic markers associated with EOC outcome and potential treatment options.See related commentary by Peres and Monteiro, p. 1604. more...
- Published
- 2021
23. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.
- Author
-
Kar, Siddhartha P, Considine, Daniel PC, Tyrer, Jonathan P, Plummer, Jasmine T, Chen, Stephanie, Dezem, Felipe S, Barbeira, Alvaro N, Rajagopal, Padma S, Rosenow, Will T, Moreno, Fernando, Bodelon, Clara, Chang-Claude, Jenny, Chenevix-Trench, Georgia, deFazio, Anna, Dörk, Thilo, Ekici, Arif B, Ewing, Ailith, Fountzilas, George, Goode, Ellen L, Hartman, Mikael, Heitz, Florian, Hillemanns, Peter, Høgdall, Estrid, Høgdall, Claus K, Huzarski, Tomasz, Jensen, Allan, Karlan, Beth Y, Khusnutdinova, Elza, Kiemeney, Lambertus A, Kjaer, Susanne K, Klapdor, Rüdiger, Köbel, Martin, Li, Jingmei, Liebrich, Clemens, May, Taymaa, Olsson, Håkan, Permuth, Jennifer B, Peterlongo, Paolo, Radice, Paolo, Ramus, Susan J, Riggan, Marjorie J, Risch, Harvey A, Saloustros, Emmanouil, Simard, Jacques, Szafron, Lukasz M, Titus, Linda, Thompson, Cheryl L, Vierkant, Robert A, Winham, Stacey J, Zheng, Wei, Doherty, Jennifer A, Berchuck, Andrew, Lawrenson, Kate, Im, Hae Kyung, Manichaikul, Ani W, Pharoah, Paul DP, Gayther, Simon A, and Schildkraut, Joellen M more...
- Subjects
Biotechnology ,Genetics ,Prevention ,Cancer ,Breast Cancer ,Human Genome ,Ovarian Cancer ,Rare Diseases ,2.1 Biological and endogenous factors - Abstract
Familial, sequencing, and genome-wide association studies (GWASs) and genetic correlation analyses have progressively unraveled the shared or pleiotropic germline genetics of breast and ovarian cancer. In this study, we aimed to leverage this shared germline genetics to improve the power of transcriptome-wide association studies (TWASs) to identify candidate breast cancer and ovarian cancer susceptibility genes. We built gene expression prediction models using the PrediXcan method in 681 breast and 295 ovarian tumors from The Cancer Genome Atlas and 211 breast and 99 ovarian normal tissue samples from the Genotype-Tissue Expression project and integrated these with GWAS meta-analysis data from the Breast Cancer Association Consortium (122,977 cases/105,974 controls) and the Ovarian Cancer Association Consortium (22,406 cases/40,941 controls). The integration was achieved through application of a pleiotropy-guided conditional/conjunction false discovery rate (FDR) approach in the setting of a TWASs. This identified 14 candidate breast cancer susceptibility genes spanning 11 genomic regions and 8 candidate ovarian cancer susceptibility genes spanning 5 genomic regions at conjunction FDR < 0.05 that were >1 Mb away from known breast and/or ovarian cancer susceptibility loci. We also identified 38 candidate breast cancer susceptibility genes and 17 candidate ovarian cancer susceptibility genes at conjunction FDR < 0.05 at known breast and/or ovarian susceptibility loci. The 22 genes identified by our cross-cancer analysis represent promising candidates that further elucidate the role of the transcriptome in mediating germline breast and ovarian cancer risk. more...
- Published
- 2021
24. Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure
- Author
-
Duus, Alberte Hjorth, Zheng, Guoqiao, Baandrup, Louise, Faber, Mette Tuxen, and Kjær, Susanne K.
- Published
- 2023
- Full Text
- View/download PDF
25. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
- Author
-
Lee, Alice W, Rosenzweig, Stacey, Wiensch, Ashley, Group, the Australian Ovarian Cancer Study, Ramus, Susan J, Menon, Usha, Gentry-Maharaj, Aleksandra, Ziogas, Argyrios, Anton-Culver, Hoda, Whittemore, Alice S, Sieh, Weiva, Rothstein, Joseph H, McGuire, Valerie, Wentzensen, Nicolas, Bandera, Elisa V, Qin, Bo, Terry, Kathryn L, Cramer, Daniel W, Titus, Linda, Schildkraut, Joellen M, Berchuck, Andrew, Goode, Ellen L, Kjaer, Susanne K, Jensen, Allan, Jordan, Susan J, Ness, Roberta B, Modugno, Francesmary, Moysich, Kirsten, Thompson, Pamela J, Goodman, Marc T, Carney, Michael E, Chang-Claude, Jenny, Rossing, Mary Anne, Harris, Holly R, Doherty, Jennifer Anne, Risch, Harvey A, Khoja, Lilah, Alimujiang, Aliya, Phung, Minh Tung, Brieger, Katharine, Mukherjee, Bhramar, Pharoah, Paul DP, Wu, Anna H, Pike, Malcolm C, Webb, Penelope M, and Pearce, Celeste Leigh more...
- Subjects
Rare Diseases ,Prevention ,Cancer ,Ovarian Cancer ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Abortion ,Induced ,Abortion ,Spontaneous ,Carcinoma ,Ovarian Epithelial ,Case-Control Studies ,Female ,Humans ,Ovarian Neoplasms ,Parity ,Pregnancy ,Risk ,United Kingdom ,United States ,Australian Ovarian Cancer Study Group ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundParity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15 case-control studies from the Ovarian Cancer Association Consortium (OCAC). Histotype-specific associations, which have not been examined previously with large sample sizes, were also evaluated.MethodsA pooled analysis of 10 470 invasive epithelial ovarian cancer cases and 16 942 controls was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between incomplete pregnancies and invasive epithelial ovarian cancer were estimated using logistic regression. All models were conditioned on OCAC study, race and ethnicity, age, and education level and adjusted for number of complete pregnancies, oral contraceptive use, and history of breastfeeding. The same approach was used for histotype-specific analyses.ResultsEver having an incomplete pregnancy was associated with a 16% reduction in ovarian cancer risk (OR = 0.84, 95% CI = 0.79 to 0.89). There was a trend of decreasing risk with increasing number of incomplete pregnancies (2-sided Ptrend < .001). An inverse association was observed for all major histotypes; it was strongest for clear cell ovarian cancer.ConclusionsIncomplete pregnancies are associated with a reduced risk of invasive epithelial ovarian cancer. Pregnancy, including incomplete pregnancy, was associated with a greater reduction in risk of clear cell ovarian cancer, but the result was broadly consistent across histotypes. Future work should focus on understanding the mechanisms underlying this reduced risk. more...
- Published
- 2021
26. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
- Author
-
Glubb, Dylan M, Thompson, Deborah J, Aben, Katja KH, Alsulimani, Ahmad, Amant, Frederic, Annibali, Daniela, Attia, John, Barricarte, Aurelio, Beckmann, Matthias W, Berchuck, Andrew, Bermisheva, Marina, Bernardini, Marcus Q, Bischof, Katharina, Bjorge, Line, Bodelon, Clara, Brand, Alison H, Brenton, James D, Brinton, Louise A, Bruinsma, Fiona, Buchanan, Daniel D, Burghaus, Stefanie, Butzow, Ralf, Cai, Hui, Carney, Michael E, Chanock, Stephen J, Chen, Chu, Chen, Xiao Qing, Chen, Zhihua, Cook, Linda S, Cunningham, Julie M, De Vivo, Immaculata, deFazio, Anna, Doherty, Jennifer A, Dörk, Thilo, du Bois, Andreas, Dunning, Alison M, Dürst, Matthias, Edwards, Todd, Edwards, Robert P, Ekici, Arif B, Ewing, Ailith, Fasching, Peter A, Ferguson, Sarah, Flanagan, James M, Fostira, Florentia, Fountzilas, George, Friedenreich, Christine M, Gao, Bo, Gaudet, Mia M, Gawełko, Jan, Gentry-Maharaj, Aleksandra, Giles, Graham G, Glasspool, Rosalind, Goodman, Marc T, Gronwald, Jacek, Harris, Holly R, Harter, Philipp, Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle AT, Hillemanns, Peter, Høgdall, Estrid, Høgdall, Claus K, Holliday, Elizabeth G, Huntsman, David G, Huzarski, Tomasz, Jakubowska, Anna, Jensen, Allan, Jones, Michael E, Karlan, Beth Y, Karnezis, Anthony, Kelley, Joseph L, Khusnutdinova, Elza, Killeen, Jeffrey L, Kjaer, Susanne K, Klapdor, Rüdiger, Köbel, Martin, Konopka, Bozena, Konstantopoulou, Irene, Kopperud, Reidun K, Koti, Madhuri, Kraft, Peter, Kupryjanczyk, Jolanta, Lambrechts, Diether, Larson, Melissa C, Le Marchand, Loic, Lele, Shashikant, Lester, Jenny, Li, Andrew J, Liang, Dong, Liebrich, Clemens, Lipworth, Loren, Lissowska, Jolanta, Lu, Lingeng, Lu, Karen H, Macciotta, Alessandra, Mattiello, Amalia, May, Taymaa, McAlpine, Jessica N, and McGuire, Valerie more...
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Oncology and Carcinogenesis ,Human Genome ,Uterine Cancer ,Genetics ,Biotechnology ,Ovarian Cancer ,Prevention ,Cancer ,Rare Diseases ,2.1 Biological and endogenous factors ,Aetiology ,Carcinoma ,Ovarian Epithelial ,Endometrial Neoplasms ,Female ,Genome-Wide Association Study ,Humans ,Ovarian Neoplasms ,Quantitative Trait Loci ,Risk Factors ,OPAL Study Group ,AOCS Group ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundAccumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers.MethodsUsing LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data.ResultsGenetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10-5). We found seven loci associated with risk for both cancers (P Bonferroni < 2.4 × 10-9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation.ConclusionsUsing cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis.ImpactOur research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings. more...
- Published
- 2021
27. Ovarian removal and subsequent breast cancer prognosis: a nationwide cohort study
- Author
-
Gottschau, Mathilde, Kjær, Susanne K., Viuff, Jakob Hansen, Jensen, Allan, Munk, Christian, Settnes, Annette, and Mellemkjær, Lene
- Published
- 2023
- Full Text
- View/download PDF
28. The influence of overweight and obesity on participation in cervical cancer screening: A systematic review and meta-analysis
- Author
-
Sand, Freja Lærke, Urbute, Aivara, Ring, Linea Landgrebe, Kjaer, Alexander K., Belmonte, Federica, and Kjaer, Susanne K.
- Published
- 2023
- Full Text
- View/download PDF
29. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
- Author
-
Brieger, Katharine K, Peterson, Siri, Lee, Alice W, Mukherjee, Bhramar, Bakulski, Kelly M, Alimujiang, Aliya, Anton-Culver, Hoda, Anglesio, Michael S, Bandera, Elisa V, Berchuck, Andrew, Bowtell, David DL, Chenevix-Trench, Georgia, Cho, Kathleen R, Cramer, Daniel W, DeFazio, Anna, Doherty, Jennifer A, Fortner, Renée T, Garsed, Dale W, Gayther, Simon A, Gentry-Maharaj, Aleksandra, Goode, Ellen L, Goodman, Marc T, Harris, Holly R, Høgdall, Estrid, Huntsman, David G, Shen, Hui, Jensen, Allan, Johnatty, Sharon E, Jordan, Susan J, Kjaer, Susanne K, Kupryjanczyk, Jolanta, Lambrechts, Diether, McLean, Karen, Menon, Usha, Modugno, Francesmary, Moysich, Kirsten, Ness, Roberta, Ramus, Susan J, Richardson, Jean, Risch, Harvey, Rossing, Mary Anne, Trabert, Britton, Wentzensen, Nicolas, Ziogas, Argyrios, Terry, Kathryn L, Wu, Anna H, Hanley, Gillian E, Pharoah, Paul, Webb, Penelope M, Pike, Malcolm C, Pearce, Celeste Leigh, and Consortium, for the Ovarian Cancer Association more...
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Estrogen ,Rare Diseases ,Cancer ,Ovarian Cancer ,Aging ,Aged ,Estrogen Replacement Therapy ,Female ,Hormone Replacement Therapy ,Humans ,Middle Aged ,Neoplasm Staging ,Neoplasm ,Residual ,Ovarian Neoplasms ,Postmenopause ,Progestins ,Progression-Free Survival ,Proportional Hazards Models ,Survival Rate ,Ovarian Cancer Association Consortium ,Paediatrics and Reproductive Medicine ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis ,Reproductive medicine - Abstract
PurposePrior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.MethodsData from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.ResultsUse of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend more...
- Published
- 2020
30. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers
- Author
-
Glubb, Dylan M, Thompson, Deborah J, Aben, Katja KH, Alsulimani, Ahmad, Amant, Frederic, Annibali, Daniela, Attia, John, Barricarte, Aurelio, Beckmann, Matthias W, Berchuck, Andrew, Bermisheva, Marina, Bernardini, Marcus Q, Bischof, Katharina, Bjorge, Line, Bodelon, Clara, Brand, Alison H, Brenton, James D, Brinton, Louise, Bruinsma, Fiona, Buchanan, Daniel D, Burghaus, Stefanie, Butzow, Ralf, Cai, Hui, Carney, Michael E, Chanock, Stephen J, Chen, Chu, Chen, Xiao Qing, Chen, Zhihua, Cook, Linda S, Cunningham, Julie M, De Vivo, Immaculata, deFazio, Anna, Doherty, Jennifer A, Dörk, Thilo, du Bois, Andreas, Dunning, Alison M, Dürst, Matthias, Edwards, Todd, Edwards, Robert P, Ekici, Arif B, Ewing, Ailith, Fasching, Peter A, Ferguson, Sarah, Flanagan, James M, Fostira, Florentia, Fountzilas, George, Friedenreich, Christine M, Gao, Bo, Gaudet, Mia M, Gawełko, Jan, Gentry-Maharaj, Aleksandra, Giles, Graham G, Glasspool, Rosalind, Goodman, Marc T, Gronwald, Jacek, Group, OPAL Study, Group, AOCS, Harris, Holly R, Harter, Philipp, Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle AT, Hillemanns, Peter, Høgdall, Estrid, Høgdall, Claus K, Holliday, Elizabeth G, Huntsman, David G, Huzarski, Tomasz, Jakubowska, Anna, Jensen, Allan, Jones, Michael E, Karlan, Beth Y, Karnezis, Anthony, Kelley, Joseph L, Khusnutdinova, Elza, Killeen, Jeffrey L, Kjaer, Susanne K, Klapdor, Rüdiger, Köbel, Martin, Konopka, Bozena, Konstantopoulou, Irene, Kopperud, Reidun K, Koti, Madhuri, Kraft, Peter, Kupryjanczyk, Jolanta, Lambrechts, Diether, Larson, Melissa C, Le Marchand, Loic, Lele, Shashikant B, Lester, Jenny, Li, Andrew J, Liang, Dong, Liebrich, Clemens, Lipworth, Loren, Lissowska, Jolanta, Lu, Lingeng, Lu, Karen H, Macciotta, Alessandra, Mattiello, Amalia, and May, Taymaa more...
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Epidemiology ,Health Sciences ,Statistics ,Mathematical Sciences ,Oncology and Carcinogenesis ,Aging ,Rare Diseases ,Human Genome ,Cancer ,Uterine Cancer ,Ovarian Cancer ,Prevention ,Biotechnology ,Aetiology ,2.1 Biological and endogenous factors - Abstract
Abstract: Accumulating evidence suggests a relationship between endometrial cancer and epithelial ovarian cancer. For example, endometrial cancer and epithelial ovarian cancer share epidemiological risk factors and molecular features observed across histotypes are held in common (e.g. serous, endometrioid and clear cell). Independent genome-wide association studies (GWAS) for endometrial cancer and epithelial ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. Using GWAS summary statistics, we explored the shared genetic etiology between endometrial cancer and epithelial ovarian cancer. Genetic correlation analysis using LD Score regression revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10−5). To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e. inverse-variance meta-analysis, co-localization, and M-values), and performed analyses by stratified by subtype. We found seven loci associated with risk for both cancers (PBonferroni < 2.4 × 10−9). In addition, four novel regions at 7p22.2, 7q22.1, 9p12 and 11q13.3 were identified at a sub-genome wide threshold (P < 5 × 10−7). Integration with promoter-associated HiChIP chromatin loops from immortalized endometrium and epithelial ovarian cell lines, and expression quantitative trait loci (eQTL) data highlighted candidate target genes for further investigation. more...
- Published
- 2020
31. Hysterectomy and risk of epithelial ovarian cancer by histologic type, endometriosis, and menopausal hormone therapy
- Author
-
Ring, Linea Landgrebe, Baandrup, Louise, Zheng, Guoqiao, Gottschau, Mathilde, Dehlendorff, Christian, Mellemkjær, Lene, and Kjaer, Susanne K.
- Published
- 2023
- Full Text
- View/download PDF
32. Tumors of the central nervous system among women treated with fertility drugs: a population-based cohort study
- Author
-
Frandsen, Clarissa L. B., Jensen, Allan, Poulsen, Frantz R., Møller, Maria, Lindquist, Sofie, Albieri, Vanna, Nøhr, Bugge, and Kjær, Susanne K.
- Published
- 2022
- Full Text
- View/download PDF
33. Population based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high grade serous ovarian cancer
- Author
-
Song, Honglin, Dicks, Ed, Tyrer, Jonathan P, Intermaggio, Maria, Chenevix-Trench, Georgia, Bowtell, David D, Traficante, Nadia, Group, AOCS, Brenton, James D, Goranova, Teodora, Hosking, Karen, Piskorz, Anna, Van Oudenhove, Elke, Doherty, Jennifer Anne, Harris, Holly R, Rossing, Mary Anne, Dürst, Matthias, Dörk, Thilo, Bogdanova, Natalia V, Modugno, Francesmary, Moysich, Kirsten B, Odunsi, Kunle, Ness, Roberta B, Karlan, Beth Y, Lester, Jenny, Jensen, Allan, Kjaer, Susanne K, Høgdall, Estrid, Campbell, Ian, Lazaro, Conxi, Pujana, Miquel Angel, Cunningham, Julie M, Vierkant, Robert A, Winham, Stacey J, Hildebrandt, Michelle AT, Huff, Chad, Li, Donghui, Wu, Xifeng, Yu, Yao, Permuth, Jennifer B, Levine, Douglas A, Schildkraut, Joellen M, Riggan, Marjorie J, Berchuck, Andrew, Webb, Penelope M, Group, OPAL Study, Cybulski, Cezary, Gronwald, Jacek, Jakubowska, Anna, Lubiński, Jan, Alsop, Jennifer, Harrington, Patricia A, Chan, Isaac, Menon, Usha, Pearce, Celeste L, Wu, Anna H, de Fazio, Anna, Kennedy, Catherine J, Goode, Ellen L, Ramus, Susan J, Gayther, Simon A, and Pharoah, Paul DP more...
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Health Sciences ,Oncology and Carcinogenesis ,Orphan Drug ,Clinical Research ,Human Genome ,Rare Diseases ,Ovarian Cancer ,Cancer ,Prevention ,2.1 Biological and endogenous factors ,Aetiology - Abstract
Abstract: Purpose: The known EOC susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian cancer susceptibility of rare deleterious germline variants in a set of candidate genes. Methods: We sequenced the coding region of 54 candidate genes in 6385 invasive EOC cases and 6115 controls of broad European ancestry. Genes with an increased frequency of putative deleterious variants in cases verses controls were further examined in an independent set of 14,146 EOC cases and 28,661 controls from the ovarian cancer association consortium and the UK Biobank. For each gene, we estimated the EOC risks and evaluated associations between germline variant status and clinical characteristics. Results: The odds ratios (OR) associated for high-grade serous ovarian cancer were 3.01 for PALB2 (95% CI 1.59 – 5.68; P = 0.00068), 1.99 for POLK (95% CI 1.15 – 3.43; P = 0.014), and 4.07 for SLX4 (95% CI 1.34-12.4; P = 0.013). Deleterious mutations in FBXO10 were associated with a reduced risk of disease (OR 0.27, 95% CI 0.07 −1.00, P=0.049). However, based on the Bayes false discovery probability, only the association for PALB2 in high-grade serous ovarian cancer is likely to represent a true positive. Conclusions: We have found strong evidence that carriers of PALB2 deleterious mutations are at increased risk of high-grade serous ovarian cancer. Whether the magnitude of risk is sufficiently high to warrant the inclusion of PALB2 in cancer gene panels for ovarian cancer risk testing is unclear; much larger sample sizes will be needed to provide sufficiently precise estimates for clinical counselling. more...
- Published
- 2019
34. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study
- Author
-
Harris, Holly R, Cushing-Haugen, Kara L, Webb, Penelope M, Nagle, Christina M, Jordan, Susan J, Group, Australian Ovarian Cancer Study, Risch, Harvey A, Rossing, Mary Anne, Doherty, Jennifer A, Goodman, Marc T, Modugno, Francesmary, Ness, Roberta B, Moysich, Kirsten B, Kjær, Susanne K, Høgdall, Estrid, Jensen, Allan, Schildkraut, Joellen M, Berchuck, Andrew, Cramer, Daniel W, Bandera, Elisa V, Rodriguez, Lorna, Wentzensen, Nicolas, Kotsopoulos, Joanne, Narod, Steven A, McLaughlin, John R, Anton-Culver, Hoda, Ziogas, Argyrios, Pearce, Celeste L, Wu, Anna H, Lindström, Sara, and Terry, Kathryn L more...
- Subjects
Epidemiology ,Health Sciences ,Ovarian Cancer ,Prevention ,Genetics ,Clinical Research ,Infertility ,Cancer ,Contraception/Reproduction ,Rare Diseases ,Reproductive health and childbirth ,Good Health and Well Being ,Adenocarcinoma ,Clear Cell ,Adenocarcinoma ,Mucinous ,Carcinoma ,Endometrioid ,Female ,Humans ,Mendelian Randomization Analysis ,Neoplasms ,Cystic ,Mucinous ,and Serous ,Ovarian Neoplasms ,Polycystic Ovary Syndrome ,Polycystic ovary syndrome ,ovarian cancer ,histotype ,Mendelian randomization ,Australian Ovarian Cancer Study Group ,Statistics ,Public Health and Health Services ,Public health - Abstract
BackgroundPolycystic ovary syndrome (PCOS) is a complex endocrine disorder with an estimated prevalence of 4-21% in reproductive aged women. Recently, the Ovarian Cancer Association Consortium (OCAC) reported a decreased risk of invasive ovarian cancer among women with self-reported PCOS. However, given the limitations of self-reported PCOS, the validity of these observed associations remains uncertain. Therefore, we sought to use Mendelian randomization with genetic markers as a proxy for PCOS, to examine the association between PCOS and ovarian cancer.MethodsUtilizing 14 single nucleotide polymorphisms (SNPs) previously associated with PCOS we assessed the association between genetically predicted PCOS and ovarian cancer risk, overall and by histotype, using summary statistics from a previously conducted genome-wide association study (GWAS) of ovarian cancer among European ancestry women within the OCAC (22 406 with invasive disease, 3103 with borderline disease and 40 941 controls).ResultsAn inverse association was observed between genetically predicted PCOS and invasive ovarian cancer risk: odds ratio (OR)=0.92 [95% confidence interval (CI)=0.85-0.99; P = 0.03]. When results were examined by histotype, the strongest inverse association was observed between genetically predicted PCOS and endometrioid tumors (OR = 0.77; 95% CI = 0.65-0.92; P = 0.003). Adjustment for individual-level body mass index, oral contraceptive use and parity did not materially change the associations.ConclusionOur study provides evidence for a relationship between PCOS and reduced ovarian cancer risk, overall and among specific histotypes of invasive ovarian cancer. These results lend support to our previous observational study results. Future studies are needed to understand mechanisms underlying this association. more...
- Published
- 2019
35. A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
- Author
-
Kim, Sehee, Wang, Miao, Tyrer, Jonathan P, Jensen, Allan, Wiensch, Ashley, Liu, Gang, Lee, Alice W, Ness, Roberta B, Salvatore, Maxwell, Tworoger, Shelley S, Whittemore, Alice S, Anton‐Culver, Hoda, Sieh, Weiva, Olson, Sara H, Berchuck, Andrew, Goode, Ellen L, Goodman, Marc T, Doherty, Jennifer Anne, Chenevix‐Trench, Georgia, Rossing, Mary Anne, Webb, Penelope M, Giles, Graham G, Terry, Kathryn L, Ziogas, Argyrios, Fortner, Renée T, Menon, Usha, Gayther, Simon A, Wu, Anna H, Song, Honglin, Brooks‐Wilson, Angela, Bandera, Elisa V, Cook, Linda S, Cramer, Daniel W, Milne, Roger L, Winham, Stacey J, Kjaer, Susanne K, Modugno, Francesmary, Thompson, Pamela J, Chang‐Claude, Jenny, Harris, Holly R, Schildkraut, Joellen M, Le, Nhu D, Wentzensen, Nico, Trabert, Britton, Høgdall, Estrid, Huntsman, David, Pike, Malcolm C, Pharoah, Paul DP, Pearce, Celeste Leigh, and Mukherjee, Bhramar more...
- Subjects
Rare Diseases ,Human Genome ,Clinical Research ,Genetics ,Patient Safety ,Cancer ,Prevention ,Ovarian Cancer ,Aetiology ,2.1 Biological and endogenous factors ,Good Health and Well Being ,Case-Control Studies ,Contraceptives ,Oral ,Hormonal ,Environment ,Environmental Exposure ,Female ,Gene-Environment Interaction ,Genetic Predisposition to Disease ,Genome-Wide Association Study ,Genotype ,Humans ,Ovarian Neoplasms ,Polymorphism ,Single Nucleotide ,Risk ,ovarian cancer ,genetics ,additive interaction ,G x E ,G × E ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
As a follow-up to genome-wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well-known ovarian cancer risk factors and their interactions with 28 genome-wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case-control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10-4 ). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46-0.60) compared to 0.71 (95%CI = 0.66-0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1-5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene-environment analysis in ovarian cancer. more...
- Published
- 2019
36. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk
- Author
-
Yang, Yaohua, Wu, Lang, Shu, Xiang, Lu, Yingchang, Shu, Xiao-Ou, Cai, Qiuyin, Beeghly-Fadiel, Alicia, Li, Bingshan, Ye, Fei, Berchuck, Andrew, Anton-Culver, Hoda, Banerjee, Susana, Benitez, Javier, Bjørge, Line, Brenton, James D, Butzow, Ralf, Campbell, Ian G, Chang-Claude, Jenny, Chen, Kexin, Cook, Linda S, Cramer, Daniel W, deFazio, Anna, Dennis, Joe, Doherty, Jennifer A, Dörk, Thilo, Eccles, Diana M, Edwards, Digna Velez, Fasching, Peter A, Fortner, Renée T, Gayther, Simon A, Giles, Graham G, Glasspool, Rosalind M, Goode, Ellen L, Goodman, Marc T, Gronwald, Jacek, Harris, Holly R, Heitz, Florian, Hildebrandt, Michelle A, Høgdall, Estrid, Høgdall, Claus K, Huntsman, David G, Kar, Siddhartha P, Karlan, Beth Y, Kelemen, Linda E, Kiemeney, Lambertus A, Kjaer, Susanne K, Koushik, Anita, Lambrechts, Diether, Le, Nhu D, Levine, Douglas A, Massuger, Leon F, Matsuo, Keitaro, May, Taymaa, McNeish, Iain A, Menon, Usha, Modugno, Francesmary, Monteiro, Alvaro N, Moorman, Patricia G, Moysich, Kirsten B, Ness, Roberta B, Nevanlinna, Heli, Olsson, Håkan, Onland-Moret, N Charlotte, Park, Sue K, Paul, James, Pearce, Celeste L, Pejovic, Tanja, Phelan, Catherine M, Pike, Malcolm C, Ramus, Susan J, Riboli, Elio, Rodriguez-Antona, Cristina, Romieu, Isabelle, Sandler, Dale P, Schildkraut, Joellen M, Setiawan, Veronica W, Shan, Kang, Siddiqui, Nadeem, Sieh, Weiva, Stampfer, Meir J, Sutphen, Rebecca, Swerdlow, Anthony J, Szafron, Lukasz M, Teo, Soo Hwang, Tworoger, Shelley S, Tyrer, Jonathan P, Webb, Penelope M, Wentzensen, Nicolas, White, Emily, Willett, Walter C, Wolk, Alicja, Woo, Yin Ling, Wu, Anna H, Yan, Li, Yannoukakos, Drakoulis, Chenevix-Trench, Georgia, Sellers, Thomas A, Pharoah, Paul DP, Zheng, Wei, and Long, Jirong more...
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Genetics ,Biotechnology ,Rare Diseases ,Ovarian Cancer ,Cancer Genomics ,Prevention ,Women's Health ,Cancer ,Clinical Research ,Human Genome ,2.1 Biological and endogenous factors ,Biomarkers ,Tumor ,Carcinoma ,Ovarian Epithelial ,Cohort Studies ,DNA Methylation ,Female ,Genetic Predisposition to Disease ,Humans ,Models ,Genetic ,Ovarian Neoplasms ,Predictive Value of Tests ,Risk ,White People ,Oncology & Carcinogenesis ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains unclear. In this study, high-density genetic and DNA methylation data in white blood cells from the Framingham Heart Study (N = 1,595) were used to build genetic models to predict DNA methylation levels. These prediction models were then applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk at a Bonferroni-corrected threshold of P < 7.94 × 10-7. Of them, 87 were located at GWAS-identified EOC susceptibility regions and two resided in a genomic region not previously reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene expression data identified consistent directions of associations across 12 CpG, five genes, and EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating expression of these five genes, namely MAPT, HOXB3, ABHD8, ARHGAP27, and SKAP1. We identified novel DNA methylation markers associated with EOC risk and propose that methylation at multiple CpG may affect EOC risk via regulation of gene expression. SIGNIFICANCE: Identification of novel DNA methylation markers associated with EOC risk suggests that methylation at multiple CpG may affect EOC risk through regulation of gene expression. more...
- Published
- 2019
37. Risk of colorectal cancer after use of fertility drugs—results from a large Danish population-based cohort of women with infertility
- Author
-
Møller, Maria, Kjær, Susanne K., Lindquist, Sofie, Brown Frandsen, Clarissa Lima, Albieri, Vanna, Viuff, Jakob Hansen, Nøhr, Bugge, Olsen, Anja, and Jensen, Allan
- Published
- 2022
- Full Text
- View/download PDF
38. Changes in HPV prevalence in Danish women with vulvar cancer during 28 years – A nationwide study of >1300 cancer cases
- Author
-
Rasmussen, Christina Louise, Thomsen, Louise T., Baandrup, Louise, Franzmann, Maria Benedicte, Larsen, Lise Grupe, Madsen, Else Mejlgaard, Salinas, Nadia Villena, Schledermann, Doris, Winberg, Birgitte Hjelm, Ørnskov, Dorthe, Waldstrøm, Marianne, and Kjaer, Susanne K. more...
- Published
- 2022
- Full Text
- View/download PDF
39. Use of hypnotics among women diagnosed with cervical cancer – A population-based cohort study
- Author
-
Horsbøl, Trine Allerslev, Kjaer, Susanne K., Andersen, Elisabeth Wreford, Ammitzbøll, Gunn, Thygesen, Lau Caspar, Johansen, Christoffer, Jensen, Pernille Tine, Frøding, Ligita Paskeviciute, Lajer, Henrik, and Dalton, Susanne Oksbjerg more...
- Published
- 2022
- Full Text
- View/download PDF
40. Survival in Women Diagnosed With Breast Cancer During Pregnancy
- Author
-
Viuff, Jakob H., Greiber, Iben K., Karlsen, Mona Aa., Storgaard, Lone, Kroman, Niels, Jensen, Maj-Britt, Eibye, Simone, Hjortshøj, Cristel S., Ejlertsen, Bent, Winther, Jeanette F., Kjær, Susanne K., and Mellemkjær, Lene more...
- Published
- 2022
- Full Text
- View/download PDF
41. Early adulthood overweight and obesity and risk of premenopausal ovarian cancer, and premenopausal breast cancer including receptor status: prospective cohort study of nearly 500,000 Danish women
- Author
-
Urbute, Aivara, Frederiksen, Kirsten, and Kjaer, Susanne K.
- Published
- 2022
- Full Text
- View/download PDF
42. Women with obesity participate less in cervical cancer screening and are more likely to have unsatisfactory smears: Results from a nationwide Danish cohort study
- Author
-
Urbute, Aivara, Kjaer, Susanne K., Kesmodel, Ulrik Schiøler, Frederiksen, Kirsten, and Thomsen, Louise T.
- Published
- 2022
- Full Text
- View/download PDF
43. Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins
- Author
-
Sand, FL, Frederiksen, Kirsten, and Kjaer, Susanne K.
- Published
- 2022
- Full Text
- View/download PDF
44. Effects of early maternal cancer and fertility treatment on the risk of adverse birth outcomes
- Author
-
Everhøj, Cathrine, Norsker, Filippa Nyboe, Rechnitzer, Catherine, Licht, Sofie de Fine, Nielsen, Thomas T, Kjær, Susanne K., Jensen, Allan, Hargreave, Marie, Christensen, Jane, Belmonte, Federica, Urhoj, Stine Kjaer, Strandberg-Larsen, Katrine, Winther, Jeanette F, and Kenborg, Line more...
- Published
- 2022
- Full Text
- View/download PDF
45. Non-aspirin NSAIDs and head and neck cancer mortality in a Danish nationwide cohort study
- Author
-
de la Cour, Cecilie D., Dehlendorff, Christian, von Buchwald, Christian, Garset-Zamani, Martin, Grønhøj, Christian, Carlander, Amanda-Louise F., Friis, Søren, and Kjaer, Susanne K.
- Published
- 2022
- Full Text
- View/download PDF
46. Trends in incidence and survival from anal cancer and incidence of high-grade anal intraepithelial neoplasia in Denmark
- Author
-
Urbute, Aivara, Munk, Christian, Sand, Freja L., Belmonte, Federica, and Kjaer, Susanne K.
- Published
- 2022
- Full Text
- View/download PDF
47. Trends in papillary thyroid cancer mortality in Denmark according to stage and education.
- Author
-
Sørensen, Sarah M., Munk, Christian, Maltesen, Thomas, Feldt‐Rasmussen, Ulla, and Kjaer, Susanne K.
- Subjects
CANCER-related mortality ,DEATH rate ,COHORT analysis ,SOCIOECONOMIC status ,REGRESSION analysis - Abstract
Objective: Few studies exist on trends in papillary thyroid cancer (PTC) survival and mortality according to stage and level of socioeconomic status. Design: Nationwide cohort study. Patients and Measurements: Patients diagnosed with PTC during 2000–2015 in Denmark were identified from the Danish Cancer Registry and followed until the end of 2020. We evaluated 5‐year all‐cause mortality and relative survival according to stage and 5‐year mortality rates with corresponding average annual percentage changes (AAPCs) according to stage and education. Finally, we assessed the association between several factors and mortality of PTC using Cox regression. Results: For the 2006 cases of PTC diagnosed during 2000–2015, relative survival tended to increase and mortality rates tended to decrease for all stages. For localized PTC, mortality rates tended to decrease among individuals with medium education (AAPC = −7.0, 95% confidence interval [CI]: −14.7 to 1.5), but showed an increasing pattern among individuals with long education (AAPC = 19.8, 95% CI: −4.2 to 50.0). For nonlocalized PTC, mortality rates showed a decreasing tendency among individuals with medium and long education (AAPC = −5.5, 95% CI: −13.2 to 2.9, and AAPC = −10.4, 95% CI: −20.8 to 1.4, respectively). Being diagnosed with PTC in a more recent calendar period and long education were associated with a lower mortality rate in the Cox regression analysis. Conclusions: A pattern of an increasing relative survival and decreasing mortality rates of PTC across all stages was seen in Denmark during 2000–2015. The decreasing pattern in mortality rates was most evident in individuals with localized stage and medium education, and in individuals with nonlocalized stage and medium or long education. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
48. Biopsy‐verified vulvar lichen sclerosus and the risk of non‐vulvar cancer: A nationwide cohort study.
- Author
-
Kaderly Rasmussen, Emma L., Hannibal, Charlotte Gerd, Hertzum‐Larsen, Rasmus, Kjær, Susanne K., and Baandrup, Louise
- Subjects
HUMAN papillomavirus ,LICHEN sclerosus et atrophicus ,DISEASE risk factors ,PAPILLOMAVIRUS diseases ,VULVAR cancer ,SQUAMOUS cell carcinoma - Abstract
Vulvar lichen sclerosus (VLS) is a chronic inflammatory mucocutaneous disease known to be associated with human papillomavirus‐independent vulvar squamous cell carcinoma. Evidence on the association with other types of cancer, however, is sparce. We conducted a large nationwide cohort study examining the incidence of non‐vulvar cancers among women with biopsy‐verified VLS compared with the general female population. By using the nationwide Pathology Registry, we identified all women in Denmark with a biopsy‐verified VLS diagnosis during 1978–2019 (n = 16,921). The cohort was followed up in the Danish Cancer Registry until 2022 for a subsequent non‐vulvar cancer diagnosis. Standardized incidence ratios (SIRs) were computed with 95% confidence intervals (CIs) as relative risk estimates of all specific non‐vulvar cancer sites. Compared with general female population rates, women with biopsy‐verified VLS had decreased rates of several non‐vulvar cancers, including HPV‐related cancers (combined estimate: SIR = 0.5; 95% CI: 0.3–0.7), and lung (SIR = 0.6; 95% CI: 0.5–0.7), liver (SIR = 0.5; 95% CI: 0.2–0.9), and thyroid cancer (SIR = 0.5; 95% CI: 0.3–0.9). The decreased SIRs tended to sustain throughout the follow‐up period following the VLS diagnosis. This large nationwide cohort study shows that women with biopsy‐verified VLS may have a long‐term reduced risk of developing HPV‐related (cervical, vaginal, oropharyngeal, and anal) and smoking‐associated cancers (lung, liver, and cervical) as well as thyroid cancer. Future studies focusing on the mechanisms behind the decreased cancer risk are needed. What's new? Vulvar lichen sclerosus (VLS) may progress to vulvar cancer risk, whereas the association with other cancer types is unknown. Here, the authors investigated the incidence of non‐vulvar cancers among women in Denmark who were diagnosed with biopsy‐verified VLS between 1978 and 2019. Relative to the general population, cancer risk was decreased among VLS patients. This was especially the case for cancers associated with human papillomavirus infection and for smoking‐related cancers. The findings suggest that VLS patients practice cancer‐avoiding behaviors or there may exist a yet unknown mechanism linking VLS with reduced risk of certain cancer types. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
49. Ovarian cancer risk factors in relation to family history.
- Author
-
Zheng, Guoqiao, Baandrup, Louise, Wang, Jiangrong, Hertzum-Larsen, Rasmus, Hannibal, Charlotte Gerd, Faber, Mette Tuxen, Sundström, Karin, and Kjær, Susanne K
- Subjects
TUBAL sterilization ,ORAL contraceptives ,DISEASE risk factors ,FAMILY relations ,HORMONE therapy ,OVARIAN cancer - Abstract
Background Women with a family history of breast and/or ovarian cancer have an increased ovarian cancer risk. Yet it remains uncertain if common ovarian cancer risk factors—especially those that are modifiable—affect this high-risk population similarly to the general population. Methods Using the Danish and Swedish nationwide registers, we established 2 nested case-control study populations in women with a family history of breast and/or ovarian cancer (2138 ovarian cancers, 85 240 controls) and women without (10 730 ovarian cancers, 429 200 controls). The overall and histology-specific associations were assessed with conditional logistic regression. The country-specific estimates were combined based on a fixed-effect assumption. Results Multiparity, hysterectomy, tubal ligation, salpingectomy, and oral contraceptive (OC) use were associated with a reduced risk of ovarian cancer in women with and without a family history, while endometriosis and menopausal hormone therapy were associated with increased risk. Multiparity and OC use presented protective effects across all histologic subtypes except mucinous ovarian cancer, which was not associated with OC use. Menopausal hormone treatment increased the risk of serous ovarian cancer but decreased the risk of the mucinous and clear cell cancers. Endometriosis was especially related to an increased risk of endometrioid and clear cell ovarian cancer. Conclusion Factors associated with a decreased ovarian cancer risk were similar between women with and without a family history of breast and/or ovarian cancer. Given the higher baseline risk for women with a family history, special attention should be paid to risk factors like endometriosis and nulliparity in this high-risk population. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
50. Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile Samples in Young Men in Denmark: Results 10 Years After Implementation of a Girls-Only HPV Vaccination Program.
- Author
-
Munk, Christian, Reinholdt, Kristian, Kjaer, Alexander K, Hemmingsen, Caroline H, Ørnskov, Dorthe, Iftner, Thomas, Waldstrøm, Marianne, and Kjaer, Susanne K
- Subjects
HUMAN papillomavirus ,HUMAN papillomavirus vaccines ,MILITARY service ,ODDS ratio ,SEXUAL partners - Abstract
Background In Denmark, a girls-only human papillomavirus (HPV) vaccination program was initiated in 2008–2009. The study aim was to assess the HPV prevalence and type distribution in younger men prior to HPV vaccination in men. Methods The study population was younger men who attended information days regarding military service. At random days (2019–2020), 280 men were included. We collected questionnaire data regarding risk factors for HPV infection and a penile swab for HPV testing. We compared results in this study with those from a previous study of young men (2006–2007). Results The majority of participants (94%) were 18–20 years old. The median number of lifetime sexual partners was 4. Altogether, 130 men (46.4%) were HPV positive. No infections with HPV types 6, 11, 16, 18, 31, and 45 were detected. The most frequent type was HPV-51 (detected in 11.1%). Comparison showed that the odds of high-risk HPV type infection were higher in 2019–2020 (prevalence odds ratio [POR], 1.7 [95% confidence interval {CI}, 1.1–2.7]) compared with 2006–2007. In contrast, the odds were lower (POR, 0.3 [95% CI,.1–.6]) for HPV types targeted by the 9-valent HPV vaccine. Conclusions The multicohort girls-only vaccination program has to a large degree protected young men against the HPV types included in the licensed vaccines. This does not speak against gender-neutral vaccination as the HPV prevalence is still high, although consisting largely of less carcinogenic HPV types. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.